Charles River (CRL) Trims 2026 Outlook After Divestitures and Leadership Changes Is The Strategy Working?

robot
Abstract generation in progress

Charles River Laboratories (CRL) reported Q4 and full-year 2025 results with lower revenue and a net loss due to asset impairments. The company then adjusted its 2026 earnings guidance, anticipating a reduction in reported revenue by over US$200 million due to planned divestitures, alongside leadership changes. This new guidance and strategic shifts aim to restore profitable growth, though risks like demand softness and cancellations persist, leading to varied analyst outlooks on future performance and fair value.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments